SCHEMBL6623669

SCHEMBL6623669

CC1(c2cc(-c3cccc(C=O)c3)ccc2O)CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 4/20 0.53
RARG P13631 4/20 0.53
PTPN11 Q06124 1/20 0.48
RARA P10276 3/20 0.45
TRIM24 O15164 2/20 0.44
TRIM33 Q9UPN9 2/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
ERN1 O75460 7/20 0.38
PGR P06401 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PTGS2 P35354 1/20 0.37
RAB9A P51151 1/20 0.37
BRD4 O60885 1/20 0.35
MCHR1 Q99705 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
ALDH5A1 P51649 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6618038 0.80 TRIM24 (0.42) TRIM24TRIM33CA12CA1CA2
SCHEMBL6705005 0.78 NAT1 (0.58) CA2
SCHEMBL6705002 0.78 NAT1 (0.58) CA2
SCHEMBL6874720 0.76 RARB (0.57) RARBRARGRARATRIM24TRIM33
SCHEMBL6619759 0.75 RARB (0.59) RARBRARGPTPN11RARATRIM24
SCHEMBL6623845 0.74 KMT2A (0.57) RAB9AALDH1A1
SCHEMBL6623846 0.74 KMT2A (0.57) RAB9AALDH1A1
SCHEMBL6620711 0.73 ERN1 (0.61) ERN1
SCHEMBL18717166 0.71 ERN1 (0.64) TRIM24TRIM33CA12CA1CA2
SCHEMBL6620084 0.71 HSP90AA1 (0.46) RARBTRIM24TRIM33CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463718-A1 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER Incyte San Diego Incorporated (US) 2004-10-06 EP disclosed
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer INCYTE SAN DIEGO INCORPORATED 2004-05-20 US disclosed
WO-2003050098-A1 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER INCYTE SAN DIEGO INCORPORATED (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer PTPA, PTPRC, PTPRCAP RARB 2680/4885RARG 2791/4885PTPN11 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.